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median age of patients was 4.8 years old (range 2–11 years) with a
median weight of 17.5 kg (range 12–38 kg). The primary data was
audited by one of the authors at a different institution (J.R.). With
12 cord blood units for 10 patients (2 double unit CBT), there were
three 6/6, three 5/6, two 4/6, and four 3/6 high resolution HLA
A/B/DR matches. To maximize cell dose, all UCB units were
depleted of plasma but not of red blood cell (RBC), and were
thawed and infused immediately without washing. No signiﬁcant
adverse events were observed after infusion despite major ABO
incompatibility in most cases. Median pre-freeze total nucleated
cell dose was 8.7  107/kg (range 4.8–15.0  107/kg), and median
pre-freeze CD34 cell dose was 4.1  105/kg (range 2.1–8.0 
105/kg) of the recipient’s body weight. One patient died of peni-
cillin-resistant S. mitis sepsis at day 8 unrelated to the CBU. All
remaining 9 patients are alive and thalassemia free with a median
follow-up time of 378 days (range 82–713 days) as of October 8,
2005. Eight patients with neutrophil engraftment showed full do-
nor chimerism by day 21 and the remaining patient achieved
stable mixed chimerism (85.6% donor’s cells) by day 162 and is
currently at day 311 post-transplant. Autologous recovery was not
seen in any of the patients. The median times to ANC 500 en-
graftment, RBC transfusion independence, and platelet 20 K en-
graftment were 14 (range 12–4 days), 35 (range 20–50 days), and
51 (range 45–60 days) days after transplantation, respectively. All
surviving patients experienced grade I-II acute GvHD that re-
solved with treatment, with no extensive chronic GvHD. The
median day to hospital discharge was day 78 (range 46–98 days).
These results show that when cell dose is optimal, unrelated CBT
may be a promising approach for the curative therapy of thalasse-
mia major.
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BUSULFAN/MELPHALAN IS AN EFFECTIVE AND WELL TOLERATED
CONDITIONING REGIMEN FOR PEDIATRIC AML AND MDS PATIENTS
RECEIVING A MATCHED SIBLING BMT
Martin, P.L.1, Driscoll, T.A.1, Szabolcs, P.1, Parikh, S.H.1,
Prasad, V.K.1, Kurtzberg, J.1 1Duke University Medical Center,
Durham, NC.
Background: Allogeneic transplant results in the best outcomes
for pediatric patients with myeloid malignancies and matched sib-
ling donors (MRD). Improvements in supportive care, prophylaxis
of infections, and treatment of GvHD has decreased non-relapse
related morbidity and mortality. Conditioning regimens without
TBI would be expected to result in less long term toxicity, but may
not be as effective in preventing relapse. We report results of
allogeneic MRD transplantation after a busulfan (Bu) and melpha-
lan (Mel) conditioning regimen for a group of 36 pediatric patients
transplanted at a single center. Methods: From 11/93–9/05, 36
children with AML or MDS received Bu (1 mg/kg/dose  16
doses) and Mel (60 mg/m2 daily 3) followed by a 5/6 or 6/6 HLA
MRD BMT. GvHD prophylaxis was CyA and MTX. Twenty-nine
patients had AML: 19 in CR1; 3 in CR2; 7 were either induction
failures or were in relapse at the time of transplant. Seven patients
had MDS: 5 were de novo patients; 1 was a patient constitutionally
mosaic for trisomy 8, and 1 was a patient with monosomy 7
following treatment for ALL. Patients were evaluated for engraft-
ment, toxicity, relapse, and overall survival. Results: All donors
were siblings, either HLA identical (n  34) or a 5/6 match caused
by a crossover event (n  2). All patients successfully engrafted
with a median time to engraftment (ANC 	 500/uL) of 14 days.
Five patients experienced grade II acute graft-versus-host disease
(aGvHD) and 3 experienced chronic GvHD (1 limited and 2
extensive). No patient died of infection, 1 died of pulmonary
toxicity, 1 patient survived an intracranial hemorrhage with neu-
rological sequela, and 1 patient survived a diffuse pulmonary alve-
olar hemorrhage. Seven AML patients relapsed (6 in marrow and
one isolated CNS chloroma) yielding a 75% disease free survival
and an 80% overall survival. All of the marrow relapsed patients
subsequently died (4 were CR1 and 2 were in relapse at the time of
BMT). All 7 MDS patients survive disease free. With a median
follow-up of 6 years the disease free and overall survival are both
29/36 (81%). Non-relapse mortality was 1 out of 36 (3%). Con-
clusions: Bu/Mel is an effective, well tolerated conditioning reg-
imen for pediatric patients with AML or MDS. Leukemic relapse,
occurring in 25% of the AML patients, remains the main cause of
treatment failure. Additional trials are indicated to verify these
results at other pediatric transplant centers.
365
UNRELATED DONOR LYMPHOCYTE INFUSIONS AS A TREATMENT OF
IMMUNODEFICIENCY IN COMPLETE DI GEORGE SYNDROME
Sedlacek, P.1, Zdrahalova, K.1, Hrusak, O.2, Mejstrikova, E.2,
Kalina, T.2, Formankova, R.1, Zizkova, H.3, Janda, A.2, Sediva, A.2,
Bartunkova, J.2, Blazek, D.4, Stary, J.1 1. Department of Pediatric
Hematology and Oncology, University Hospital Motol, Prague, Czech
Republic; 2. Department of Immunology, University Hospital Motol,
Prague, Czech Republic; 3. Institute of Hematology and Blood Transfu-
sion, Prague, Czech Republic; 4. Department of Anesthesiology,Univer-
sity Hospital Motol, Prague, Czech Republic.
Complete DiGeorge syndrome (DGS) is a rare congenital dis-
order characterized by number of developmental defects and T-
cell deﬁciency. We present an infant with multiple anomalies
(choanal and esophageal atresia, coloboma, tracheobronchomala-
cia, etc.), diagnosed at the age of 2 months with complete DGS
(absence of T cells, no response to mitogens, absent thymus),
treated with unrelated donor lymphocyte infusion (DLI). During
ﬁrst 7 months of age he required long-term ventilation, suffered
recurrent infections, and sepsis. He had no sibling and no fully
matched unrelated donor was available. At the age of 6 months the
ﬁrst dose of DLI (1  106 /kg CD3; 2 105/kg CD34) was
administered to him from an unrelated donor (mismatched for B
and Cw alleles) with no conditioning regimen and no graft versus
host disease (GVHD) prophylaxis. Ten days after DLI, he devel-
oped severe acute GVHD (skin stage 3–4) complicated with sepsis,
cardiopulmonary instability, capillary leak syndrome, and ileus. He
was treated with antithymocyte globulin (rATG), cyclosporin A
(CsA), and steroids with a complete resolution of GVHD. On day
36 after ﬁrst DL, he was given the second DLI (0.9  106/kg
CD3) with no conditioning and GVHD prophylaxis consisting
of continued CsA. EBV infection has appeared 4 weeks after
infusion (peripheral expansion of CD8 donor cells started), suc-
cessfully treated with CsA withdrawal and rituximab. Isolated cho-
lestatic liver GVHD manifested month after second DLI, pro-
gressed to stage 4, successfully treated with steroids, CsA, and
rATG. Since day 10 after ﬁrst DLI, the donor genotype due to
presence of donor T cells is documented in VNTR. Response to
mitogens appeared and is now comparable to healthy controls.
Central memory (CD27pos, CD45RAneg) stages dominate in the
peripheral blood CD4 and CD8 cells (64 to 81% and 52 to 95%,
respectively), which was higher than in control. Effector memory
cells are increased in CD4 subset, decreased in CD8. Naive CD4
T cells (CD45RApos, CD27pos) continued to be completely absent
at all time-point measured, but naive CD8 (CD45RApos, CD27pos)
were detected already at D 100 at 5% and continued raise
thereafter. The patient is now 10 months after ﬁrst DLI still on
CsA and steroids, slowly started to gain his developmental mile-
stones. We believe that infusions of small doses of DLI from an
unrelated donor represent an adequate therapy for complete Di-
George syndrome. Supported by NI 7410-3, MSM0021620812.
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS WITH WISKOTT
ALDRICH SYNDROME (WAS): ANALYSIS OF 19 PTS TRANSPLANTED IN
BRAZIL AND CHILE
Bonﬁm, C.1, Barriga, F.2, Wietstruck, M.A.2, Setubal, D., Ruiz, J.1,
Funke, V.1, Koliski, A.3, Bitencourt, M.1, Pasquini, R.1 1. Federal
University of Parana, Curitiba, PR, Brazil; 2. Pontiﬁcia Universidad
Catolica, Santiago, Chile; 3. Pediatric Intensive Care Unit, Curitiba,
PR, Brazil.
WAS is a rare X linked disorder characterized by eczema, throm-
bocytopenia with small platelets, and increased susceptibility to
infections autoimmune diseases and malignancies. SCT from
matched related or unrelated donors is considered the treatment of
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choice for young patients (pts) with severe manifestations of the
disease. In this study, we analyze the results in 19 boys transplanted
in 2 BMT centers between 04/92–03/05. Age: 7 months to 14 years
(M: 2 years). All but one pt had the classical syndrome with many
serious infections (especially CMV related) or autoimmunity prior
to transplant.Stem cell source: Bone marrow from related: 9 pts or
cord blood (CB) from unrelated donors:10 pts. HLA disparities:
Bone marrow: 6/6: 7 pts and 5/6: 2 pts; CB: 6/6: 1 pt, 5/6: 6 pts and
4/6: 3 pts. Preparatory regimen: Busulfan(BU)  Cyclophospha-
mide(CY)  ATG: 17 pts; BU  Fludara: 1 pt, and BU  CY 
Thiotepa: 1 pt. GVHD prophylaxis:cyclosporine (csa)  metho-
trexate: 8 pts; csa  steroids: 10 pts, and csa  MMF: 1 pt. ATG
was added to pts receiving transplants from donors other than
HLA identical siblings. TNC infused: bone marrow 2, 3—10 
108/kg (M: 3, 08) and CB: 4, 9mdash;8,8–107/kg (6, 12).
Sixteen pts (84%) are alive between 117 to 3997 days (M: 776 days)
after SCT. All pts survived more than 28 days and were evaluable
for engraftment. Mucositis grade I-II occurred in most pts. VOD
(mild): 2 pts. Three pts died on day 34 (Unrelated CB 4/6,
pulmonary aspergilosis), day 65, and day 117 (HLA identical
siblingsmdash;CMV pneumonitis). Primary graft failure occurred
in 2 pts who received Unrelated 4/6 CB and only 1 pt is alive and
well on day 370 after the second CB infusion. This pt developed
acute (grade III) and chronic (extensive) GVHD and many other
severe viral infections. Seventeen pts engrafted and the median
time to reach ANC 	 500/ul was 22 days (10–30) and platelets 	
20.000/ul was 35 days (14–77). Acute GVHD occurred in 7/17 pts
(only one pt grade IV) and chronic GVHD in 3/16 pts (extensive
and severe). Three pts are still receiving treatment with immuno-
supressive drugs. Full donor chimerism was achieved in 15/16
surviving pts.Viral infections were frequent complications, espe-
cially in the URD cord blood transplants.We conclude that SCT in
pts with WAS has an excellent survival and should be indicated to
young pts with severe manifestations of the disease.
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EARLY HEPATIC COMPLICATION IN FIRST YEAR AFTER BONE MARROW
TRANSPLANTATION IN MAJOR THALASSEMIA PATIENTS
Iravani, M.1, Nedaeifard, L.1, Arshy, M.1, Toutounchi, M.1,
Ghavamzadeh, A.1 1Hematology-Oncology and BMT Research Center,
Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Liver complications are one of the major causes of morbidity
and mortality following BMT. Determination of the factors of
liver injury leads to earlier diagnosis after BMT and improves
prognosis. We studied 113 major thalassemic patients who
have been transplanted from 1990–2000 in bone marrow trans-
plantation center of Shariati Hospital. Sixty-two were male and
51 were female. Twenty-seven patients were class 1, 56 were
class 2, and 30 were class 3. The median age of each class were
6.5, 6.3, and 8.7 year. Conditioning regimen consisted of busul-
fan (3.5–4 mg/Kg) and cyclophophamide (40–50 mg/Kg).For
GVHD prophylaxis we gave cyclosporine  metothoroxate.
Grade of liver ﬁbrosis was deﬁned by biopsy in all patients
before BMT. All patients and their donors tested for HBSAg,
HBSAb, HCVAb, and CMVAb with RIA method. We assessed
causes of liver dysfunction before and after transplantation and
effect of high ferritin level on liver function. Hepatic dysfunc-
tion in ﬁrst year after transplantation was seen in 86 (76%)
patients. Causes of liver dysfunction consisted of 53.1%
GVHD, 15.93% cyclosporine hepatotoxicity, 7.07% condition-
ing regimen hepatotoxicity, and VOD. In all three classes he-
patic GVHD, cyclosporine toxicity, death, and normal liver
function post BMT had signiﬁcant relation with hepatic dys-
function before BMT (P  .001). In patients with ferritin level
more than 1000, there was signiﬁcant hepatotoxicity with con-
ditioning regimen (P  .001). According to our study, hepatic
GVHD (%53.1) is the most common cause of hepatic dysfunc-
tion in all three classes.
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BOOSTING OF THYMIC T LYMPHOCYTE MATURATION AND EXPORT BY
INFUSION OF T CELL DEPLETED DONOR PERIPHERAL BLOOD STEM
CELLS TO A SCID PATIENT WITH DECLINING T LYMPHOCYTE COUNTS
AFTER HLA MISMATCH ALLOGENEIC BMT
Jacobsen, N.1, Dickmeiss, E.2, Heilmann, C.3, Madsen, H.O.2,
Svejgaard, A.2, Dupont, B.4, Ryder, L.2 1. Dept of Haematology, Rig-
shospitalet, Copenhagen, Denmark; 2. Dept of Clin Immunol, Rigshos-
pitalet, Copenhagen, Denmark; 3. Paediatric Clinic II, Rigshospitalet,
Copenhagen, Denmark; 4. Dept of Medicine and Immunol Program.
Mermorial Sloan-Kettering Cancer Center, New York, NY.
The patient was born June 1971. The diagnosis of SCID was
established at 3 months of age. Retrospective analysis revealed
JAK3 mutations compatible with autosomal recessive SCID. In
December 1971, he was treated with 3 infusions of BM aspirates,
totaling 7 107 nucleated cells from his mother’s brother, selected
because of a negative donor versus recipient MLR. Retrospective
HLA-typing revealed DRB1 and DQB1 identity but multiple class
I mismatches. No conditioning or GvHD prophylaxis was given. A
skin rash was observed 2 weeks after the ﬁrst infusion. No other
signs of GvHD occurred. The lymphocyte count was 5100 per mL
one year after transplantation, ca. 50% of the PBMC expressed the
not shared donor derived HLA class I antigens and 63% were
SRBC rosetting cells. Mitogen responses were normalized but
there was persistent absence of donor derived Rh(D) positive red
blood cells and of IgG and IgA production, whereas IgM isoag-
glutinin developed normally. Low blood T lymphocyte count was
noted in 1988. In 2000, the blood CD4 count was decreased to
200 per mL, and the CD8 count to 300 per mL. The TRECs
containing CD4 cell count was 0.02 per mL and the TRECs
containing CD8 cell count 0.03 per mL (1 to 2% of normal for
age). Bone marrow CD34 cells, peripheral blood neutrophils,
and B lymphocytes were of recipient origin, whereas the few
circulating T lymphocytes were of donor origin (microsatellite
analysis). A peripheral blood stem cell harvest was procured (De-
cember 2001) from the original donor and CD34 puriﬁed using
the CliniMACS device and the CliniMACS CD34 reagent set. The
patient received a total of 2.7  106 CD34 cells and 0.08  104
CD3 cells per kg BW. Cyclosporin was given for 3 month as
GvHD prophylaxis. No evidence of GvHD occurred. Subsequent
blood tests have shown no major change in the number of circu-
lating CD3, CD4 CD45RA, or CD8 CD45RA lymphocytes
over time. However, the number of CD4 and CD8 cells containing
TRECs increased within the 600 days after boosting to 1.5 and 2.5
per mL, respectively, (normal for recipient age). A subsequent
decline has been observed. We conclude that descendants from the
boosting donor CD34 cells were able to undergo maturation in
the thymus but a persistent take of donor derived CD34 cells was
not established.
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BUSULFEX, CYCLOPHOSPHAMIDE, THYMOGLOBULIN (BU/CY/
Thymo) AS PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH NON-
MALIGNANT DISORDERS (NMD)
Gross, T.G.1, Orchard, P.2, Termuhlen, A.M.1, Baker, K.S.2 1. Ohio
State University/Children’s Hospital, Columbus, OH; 2. University of
Minnesota, Minneapolis, MN.
Background: Graft failure and GVHD remain major causes of
failure in HSCT for children with non-malignant disorders (MND).
Oral busulfan (BU), cyclophosphamide (CY), equine antithymocyte
globulin (ATG) is a standard preparative used for children with
NMD. We present preliminary data for a preparative regimen of
Bulsufex®, cyclophosphamide, and Thymoglobulin® (BU/CY/
Thymo). The regimen was developed for ease of administrtion, es-
pecially for young children, and theorectic reduction of GVHD sec-
ondary to more in vivo T cell depletion associated with
Thymoglobulin® compared to equine ATG.Methods:The regimen
included Busulfex® [0.8 mg/kg (	12 kg) or 1.1 mg/kg (12 kg)] q6
hour  16 (dose adjusted to target AUC  1125 M-minute). Cy-
clophosphamide (50 mg/kg/day  4), Thymoglobulin® (2.5 mg/kg/
day  4) with CSA and short course MTX (or methylpredisone for
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